IL101243A
(en)
*
|
1991-03-20 |
1999-12-22 |
Merck & Co Inc |
Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
|
NZ257993A
(en)
*
|
1992-11-04 |
1997-05-26 |
Sepracor Inc |
Use of (+)-doxazosin and medicament containing the compound
|
AU5549494A
(en)
*
|
1992-11-04 |
1994-05-24 |
Sepracor, Inc. |
Methods and compositions of (+) doxazosin for the treatment of hypertension
|
US5294615A
(en)
*
|
1993-04-29 |
1994-03-15 |
Abbott Laboratories |
Terazosin polymorph and pharmaceutical composition
|
US5412095A
(en)
*
|
1993-04-29 |
1995-05-02 |
Abbott Laboratories |
Terazosin monohydrochloride and processes and intermediate for its production
|
US5504207A
(en)
*
|
1994-10-18 |
1996-04-02 |
Abbott Laboratories |
Process and intermediate for the preparation of terazosin hydrochloride dihydrate
|
US5587377A
(en)
*
|
1995-10-24 |
1996-12-24 |
Invamed, Inc. |
Terazosin crystalline polymorph and pharmaceutical compositions thereof
|
JPH11507395A
(ja)
*
|
1995-11-15 |
1999-06-29 |
メルク エンド カンパニー インコーポレーテッド |
アルファ1a アドレナリン受容体拮抗薬
|
DE19546573A1
(de)
*
|
1995-12-13 |
1997-06-19 |
Uetikon Chemie Gmbh |
Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
|
US5952003A
(en)
*
|
1996-08-01 |
1999-09-14 |
Novartis Corporation |
Terazosin capsules
|
US5922722A
(en)
*
|
1996-11-12 |
1999-07-13 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
IT1286789B1
(it)
*
|
1996-11-29 |
1998-07-17 |
Alfa Chem Ital |
Processo per la produzione della forma i del terazosin monocloridato anidro
|
GB9708917D0
(en)
*
|
1997-05-01 |
1997-06-25 |
Pfizer Ltd |
Compounds useful in therapy
|
US6214832B1
(en)
|
1997-06-18 |
2001-04-10 |
Merck & Co., Inc. |
Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
|
US6376503B1
(en)
|
1997-06-18 |
2002-04-23 |
Merck & Co., Inc |
Alpha 1a adrenergic receptor antagonists
|
US6080760A
(en)
*
|
1997-06-18 |
2000-06-27 |
Merck & Co., Inc. |
Alpha 1A adrenergic receptor antagonists
|
US6143750A
(en)
*
|
1997-06-18 |
2000-11-07 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
US6057350A
(en)
*
|
1997-06-18 |
2000-05-02 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
US6037354A
(en)
|
1997-06-18 |
2000-03-14 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
US6248888B1
(en)
|
1997-11-14 |
2001-06-19 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of terazosin hydrochloride dihydrate
|
AU5234899A
(en)
|
1998-07-30 |
2000-02-21 |
Merck & Co., Inc. |
Alpha 1a adrenergic receptor antagonists
|
AU1808400A
(en)
|
1998-10-29 |
2000-05-22 |
Merck & Co., Inc. |
Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists
|
US6319932B1
(en)
|
1998-11-10 |
2001-11-20 |
Merck & Co., Inc. |
Oxazolidinones useful as alpha 1A adrenoceptor antagonists
|
US6228870B1
(en)
|
1998-11-10 |
2001-05-08 |
Merck & Co., Inc. |
Oxazolidinones useful as alpha 1a adrenoceptor antagonists
|
AU1345600A
(en)
|
1998-11-12 |
2000-06-05 |
Merck & Co., Inc. |
Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
|
DE19861323B4
(de)
*
|
1998-12-08 |
2006-02-16 |
Robert Bosch Gmbh |
Verfahren zur Übertragung von Kurznachrichten
|
DE19856440C2
(de)
*
|
1998-12-08 |
2002-04-04 |
Bosch Gmbh Robert |
Übertragungsrahmen und Funkeinheit mit Übertragungsrahmen
|
US6358959B1
(en)
|
1999-01-26 |
2002-03-19 |
Merck & Co., Inc. |
Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
|
GB2355456A
(en)
|
1999-09-30 |
2001-04-25 |
Merck & Co Inc |
Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
|
GB2355263A
(en)
|
1999-09-30 |
2001-04-18 |
Merck & Co Inc |
Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
|
GB2355457A
(en)
|
1999-09-30 |
2001-04-25 |
Merck & Co Inc |
Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
|
GB2355264A
(en)
|
1999-09-30 |
2001-04-18 |
Merck & Co Inc |
Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
|
US6200573B1
(en)
|
1999-12-03 |
2001-03-13 |
Starcor Pharmaceuticals, Inc. |
Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
|
US7335803B2
(en)
|
2001-10-19 |
2008-02-26 |
Allergan, Inc. |
Methods and compositions for modulating alpha adrenergic receptor activity
|
US6313172B1
(en)
|
2000-04-13 |
2001-11-06 |
Allergan Sales, Inc. |
Methods and compositions for modulating alpha adrenergic receptor activity
|
JP2002121188A
(ja)
*
|
2000-07-18 |
2002-04-23 |
Toray Ind Inc |
ピペラジンアミド化合物の製造法およびピペラジンテトラヒドロフラン−2−カルボン酸アミド誘導体
|
US20020198215A1
(en)
*
|
2000-10-23 |
2002-12-26 |
Lino Tavares |
Terazosin transdermal device and methods
|
US6534542B2
(en)
|
2001-02-27 |
2003-03-18 |
Allergen Sales, Inc. |
(2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
|
KR20040088519A
(ko)
|
2002-02-22 |
2004-10-16 |
뉴 리버 파마슈티칼스, 인크. |
활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
|
US7358269B2
(en)
|
2002-05-21 |
2008-04-15 |
Allergan, Inc. |
2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
|
US7276522B2
(en)
|
2002-05-21 |
2007-10-02 |
Allergan, Inc. |
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
|
US7323485B2
(en)
|
2002-05-21 |
2008-01-29 |
Allergan, Inc. |
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
|
US7091232B2
(en)
|
2002-05-21 |
2006-08-15 |
Allergan, Inc. |
4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
|
EP2335734A3
(de)
|
2003-09-12 |
2012-01-11 |
Allergan, Inc. |
Behandlung von Schmerzen und weitere alpha-2-adrenergisch beeinflüsste Zustanden
|
US7390829B2
(en)
|
2005-06-29 |
2008-06-24 |
Allergan, Inc. |
Alpha-2 adrenergic agonists
|
US7323477B2
(en)
|
2006-02-02 |
2008-01-29 |
Allergan, Inc. |
7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
|
AU2007286186A1
(en)
*
|
2006-08-08 |
2008-02-21 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
|
US7598417B2
(en)
|
2007-04-12 |
2009-10-06 |
Allergan, Inc. |
Substituted fluoroethyl ureas as alpha 2 adrenergic agents
|
AU2008254717B2
(en)
|
2007-05-23 |
2014-06-05 |
Allergan, Inc. |
Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure
|
CA2687976C
(en)
|
2007-05-23 |
2015-04-07 |
Allergan, Inc. |
Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
|
US7902247B2
(en)
|
2008-01-09 |
2011-03-08 |
Allergan, Inc. |
Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
|
US7829587B2
(en)
|
2008-01-09 |
2010-11-09 |
Allergan, Inc. |
Substituted 2-aminotetralin derivatives as selective alpha 2B agonist
|
US8809379B2
(en)
|
2008-01-18 |
2014-08-19 |
Allergan, Inc. |
Selective subtype alpha 2 adrenergic agents and methods for use thereof
|
US8362022B2
(en)
|
2008-01-18 |
2013-01-29 |
Allergan, Inc. |
Selective subtype alpha 2 adrenergic agents and methods for use thereof
|
US20090239918A1
(en)
*
|
2008-03-24 |
2009-09-24 |
Allergan, Inc. |
Selective subtype alpha 2 adrenergic agents and methods for use thereof
|
US8420114B2
(en)
|
2008-04-18 |
2013-04-16 |
Warsaw Orthopedic, Inc. |
Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
|
US9072727B2
(en)
|
2008-04-18 |
2015-07-07 |
Warsaw Orthopedic, Inc. |
Alpha adrenergic receptor agonists for treatment of degenerative disc disease
|
EP2280707A1
(de)
|
2008-05-05 |
2011-02-09 |
Allergan, Inc. |
Alpha2b- und alpha2c-agonisten
|
AU2009246572A1
(en)
|
2008-05-16 |
2009-11-19 |
Allergan, Inc. |
Selective subtype alpha 2 adrenergic agents and methods for use thereof
|
AU2009333620A1
(en)
|
2008-12-08 |
2011-07-07 |
Allergan, Inc. |
N-(1-phenyl-2-arylethyl)-4,5-dihydro-3H-pyrrol-2-amine compounds as subtype selective modulators of alpha2B or alpha2B and alpha2C adrenoceptors
|
US20110306635A1
(en)
|
2009-02-06 |
2011-12-15 |
Allergan ,Inc. |
Pyridine compounds as subtype selective modulators of alpha2b and /or alpha 2c adrenergic receptors
|
EP2459542B1
(de)
|
2009-07-30 |
2014-10-29 |
Allergan, Inc. |
Substituierte N-Benzyl-4,5-Dihydrooxazol-2-Amine als selective alpha-2B/2C-Rezeptoragonisten
|
EP2486009B1
(de)
|
2009-10-06 |
2019-08-21 |
Allergan, Inc. |
2h-pyrrol-5-aminderivate als alpha adrenorezeptormodulatoren
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
US11224572B1
(en)
*
|
2020-08-17 |
2022-01-18 |
Novitium Pharma LLC |
Stable oral liquid composition of terazosin
|